Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
May 17, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Otsuka Pharmaceutical Development & Commercialization, Inc. Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool
May 09, 2018 23:01 ET
|
Open Minds
Gettysburg, PA, May 09, 2018 (GLOBE NEWSWIRE) -- Nearly 3.4 million adults, or 1.1% of the U.S. population, are affected by schizophrenia.1,2 As a chronic, relapsing condition, those who have...
Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
December 19, 2017 08:00 ET
|
Minerva Neurosciences, Inc
Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...
Schizophrenia Relapse Reduction Disease Management Program – New Resources Released By Frameworks In Health & Quality
September 30, 2017 10:02 ET
|
Open Minds
Gettysburg, PA, Sept. 30, 2017 (GLOBE NEWSWIRE) -- OPEN MINDS announced Otsuka Pharmaceutical Development & Commercialization, Inc. has released a new Frameworks in Health and Quality program,...
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
February 21, 2017 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
January 20, 2017 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
October 26, 2016 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Mental Health Patient Designs Tool for Schizophrenia App During Mental Health Awareness Week
October 03, 2016 09:51 ET
|
Self Care Catalysts
TORONTO, ON--(Marketwired - October 03, 2016) - Self Care Catalysts, a patient intelligence and solutions company, is partnering with mental health advocate and Schizophrenia patient Kristy Speaks to...
Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia
May 26, 2016 08:00 ET
|
Minerva Neurosciences, Inc
Statistically significant improvement in PANSS negative symptoms and total PANSS scores observed MIN-101 shown to be statistically superior on key secondary endpoints Effect of MIN-101...
Hopewell Develops New Assessment Tool; Indicates Whether Therapeutic Farm is Best for Individuals
May 05, 2015 13:28 ET
|
Hopewell
Mesopotamia, OH, May 5, 2015 (GLOBE NEWSWIRE) -- The first step in getting treatment for mental illness is
attaining a correct assessment and diagnosis. This can be
difficult as mental health...